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The autoimmune/inflammatory syndrome induced by adjuvants (ASIA), presented by 
Shoenfeld and Agmon-Levin in 2011, is an entity that incorporates diverse autoimmune 
conditions induced by the exposure to various adjuvants. Adjuvants are agents that 
entail the capability to induce immune reactions. Adjuvants are found in many vaccines 
and used mainly to increase the response to vaccination in the general population. 
Silicone has also been reported to be able to induce diverse immune reactions. Clinical 
cases and series of heterogeneous autoimmune conditions including systemic sclero-
sis, systemic lupus erythematosus, and rheumatoid arthritis have been reported to be 
induced by several adjuvants. However, only a small number of cases of autoimmune 
thyroid disorder have been included under the umbrella of ASIA syndrome. Indeed, 
clinical cases of Hashimoto’s thyroiditis and/or subacute thyroiditis were observed after 
the exposure to vaccines as well as silicone implantation. In our review, we aimed to 
summarize the current knowledge on ASIA syndrome presented as endocrinopathies, 
focusing on autoimmune thyroid disorders associated with the various adjuvants.
Keywords: autoimmune/inflammatory syndrome induced by adjuvants, thyroid, endocrinopathy, adjuvants, 
vaccines, silicone, Hashimoto’s thyroiditis, Graves disease
iNTRODUCTiON
Adjuvants are substances that are able to trigger autoimmunity via a variety of mechanisms, such as 
alteration of the host’s immune system, polyclonal activation of B cells, effects on cellular immunity, 
immunoregulatory cells, viral-induced antibodies, and acceleration of molecular mimicry (1). 
Exposure to adjuvants can occur in a variety of methods due to their wide range of uses in vaccines, 
mineral oils, silicone implants, and many other products and devices. The association between 
adjuvant exposure and autoimmunity manifests itself in five autoimmune conditions sharing simi-
lar autoimmunity manifestations (2, 3), such as the postvaccination phenomena, the macrophagic 
myofasciitis syndrome (MMF), the Gulf war syndrome (GWS), siliconosis, and the sick building 
syndrome (SBS) (4, 5). The autoimmune/inflammatory syndrome induced by adjuvants (ASIA), 
presented by Shoenfeld and Agmon-Levin (6) in 2011, is a single entity that incorporates all five 
conditions. Extensive research has identified the genetic background, contributing to the develop-
ment of ASIA syndrome in predisposed individuals following adjuvant exposure. A large number of 
autoimmune diseases share several alleles of the HLA class II such as DRB1 locus. The development 
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of specific autoantibodies is determined by DRB1 alleles leading 
to an abnormal response and development of full-blown autoim-
mune diseases (7, 8).
When used in vaccines, adjuvants are purposely used as 
immunogenicity enhancing agents that are essential for direct-
ing the adaptive immunoresponse (9). However, they might also 
trigger undesired autoimmune reactions that question the use 
of adjuvants and their safety in the context of DRB1*01 genetic 
background (10).
A systematic review by Jara et  al. (4) reported that 4479 
ASIA cases have been identified since its presentation in 2011. 
Among them, 305 were considered severe, with the majority of 
these cases being developed following vaccines mainly directed 
to HPV, HBV, and seasonal influenza. Despite vaccines’ proven 
record of safety and efficiency, aluminum hydroxide was used in 
these vaccines along with the viral antigens as an adjuvant. Due 
to aluminum’s capability to enhance the immunoresponse, it ena-
bles the usage of smaller amount of antigens. However, enhanced 
immunogenicity might lead to enhanced reactogenicity in a pro-
cess not always benign involving pathological stimulation (11).
The other adjuvants containing products yielding severe 
clinical manifestations are silicone implants and mineral oil fillers 
(4, 12).
Silicone has been considered as an inert material, which 
is unable to induce immune reactions in the human body. 
Therefore, it has been used in many medical devices for the last 
60  years, including both silicone and saline breast implants. 
However, a possible association between silicone exposure and 
autoimmune diseases has been reported in many studies demon-
strating the development of autoimmune diseases and autoan-
tibodies in patients following exposure to silicone implants 
(13, 14). Improved clinical manifestations after the extraction 
of implants (15) support the relationship between silicone and 
autoimmunity.
Mineral oil injections, which are prevalent in Mexico and 
Latin America for cosmetic uses, have been identified as a leading 
cause of ASIA syndrome as well via the proposed mechanism of 
chronic inflammation induction leading to granuloma formation 
and thickening of the dermis (4, 10).
The risk for autoimmune diseases, determined by the patient’s 
genetic background, is increased in patients with autoimmune 
diseases history such as type 1 diabetes mellitus (T1DM). Thyroid 
antibodies can be identified in approximately 20–25% of patients 
with type 1 diabetes, and up to 50% of them progress to clinical 
autoimmune thyroid disease (AITD) (16). Thyroid autoimmune 
diseases have been described in many case reports and case series, 
presenting thyroid autoimmune manifestations along with other 
autoimmune conditions.
In genetically predisposed individuals, under particular 
conditions, molecular mimicry between microbial and human 
antigens has been shown to be able to turn a defensive immu-
noresponse into autoimmune response. This mechanism has yet 
to be explored in the field of thyroid autoimmune diseases (17). In 
our review, we aimed to summarize the current knowledge about 
ASIA syndrome and the relationship between adjuvants and 
autoimmune diseases, focusing on its association with autoim-
mune endocrinopathies and thyroid autoimmunity.
eNDOCRiNOPATHY AND ASiA 
SYNDROMe
Pathological processes of the endocrine glands result in abnor-
mal levels of circulating hormones, which lead to endocrinopa-
thies. Some endocrine disorders are immune mediated, such 
as Hashimoto’s thyroiditis (HT), Graves’ disease, and T1DM 
(18–20). Thus, it is possible that endocrine autoimmune diseases 
can be triggered by adjuvants, configuring cases of ASIA syn-
drome. Case reports, cohort and case–control studies on ASIA 
syndrome, and the majority of the endocrinopathies are still 
scarce. Lately, primary ovarian failure (POF) has been linked to 
ASIA, especially after vaccination (21–25).
Primary ovarian failure or premature ovarian insufficiency 
is defined as a combination of amenorrhea, for a minimum of 
4  months, decline in sex steroids, and follicle-stimulating hor-
mone (FSH) above 40 IU/l at two measurements with an interval 
of at least 1 month in women younger than 40 years (26). POF is 
a disorder with multiple etiologic mechanisms. The presence of 
lymphocytic invasion in the oophorus and the identification of 
autoantibodies against ovarium antigens on the theca, granulose, 
corpus luteum, and zona pellucida (27–29) support the idea 
that part of its etiology, estimated in 20–30% (30), is immune 
mediated. Furthermore, POF is commonly associated with other 
autoimmune diseases, including Addison’s disease, thyroiditis, 
autoimmune polyglandular syndrome, systemic lupus erythe-
matosus (SLE), hemolytic anemia, idiopathic thrombocytopenic 
purpura (ITP), and Sjogren’s syndrome (31). The pathogenesis 
of POF also involves genetic mutations, metabolic disorders, 
and environmental factors, such as virus infection, chemo and 
radiotherapy, and surgeries (30).
HPV vaccine has been reported as an important issue in ASIA 
syndrome, already being related, for instance, to Guillain-Barré 
syndrome and other neuropathies, such as SLE, vasculitis, ITP, 
and autoimmune hepatitis (32–36). Developing autoimmune 
diseases as an adverse effect of the vaccine can be both due to 
its HPV virus-like particles, which have potent immuno-stim-
ulatory properties (and can induce autoimmunity by molecular 
mimicry, epitope spreading, bystander activation, and polyclonal 
activation) (37), and due to the presence of aluminum as an 
adjuvant in the vaccine (38). Adjuvants are capable of increasing, 
intensifying, and prolonging antigen-specific immunoresponse 
of the vaccines without holding its own specific antigenic effect 
(38). Autoimmune well-defined diseases, as well as the non-
specific immune disorders, following vaccination can present as 
a subacute vaccination side effect or appear months or years after 
the boosters (39–43). Genetically predisposed patients are more 
likely to exhibit late manifestations and are in a higher risk of 
developing ASIA syndrome (36, 44).
Colafrancesco et al. (21) recently reported three cases of POF 
following immunization with HPV vaccine. The three patients 
fulfilled the criteria for ASIA syndrome suggested by Shoenfeld 
and Agmon-Levin (6). They described three young women, 
previously healthy and with normal sexual development, who 
received three administrations of the quadrivalent HPV vaccine. 
The patients experienced general symptoms, including nausea, 
stomachaches, heavy and burning sensations in the injected arm, 
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headaches, insomnia, arthralgia, depression, anxiety, and dif-
ficulty in concentrating, and then presented amenorrhea within 
approximately 10 months, 2 years, and 10 years after the first dose. 
Two of them were positive for previously negative antibodies 
(anti-TPO and antiovarian). Hormonal screening was per-
formed, showing increased FSH and luteinizing hormone (LH) 
plus extremely low levels of estradiol. Pregnancy was excluded, 
as well as no abnormalities were revealed in the transvaginal and 
pelvic ultrasound. After a karyotype evaluation and search for 
Fragile X syndrome with no aberrations, they were diagnosed 
with POF. Moreover, two of the three patients were siblings lead-
ing to the hypothesis that may exist as a rare risk factor for this 
adverse effect.
Little and Ward (22) also reported a case of POF succeed-
ing HPV vaccination, in a 16-year-old patient, who presented 
irregular menses after taking the quadrivalent vaccine, followed 
by oligomenorrhea and amenorrhea. Her hormone profile also 
showed high levels of FSH and LH and low levels of estradiol and 
anti-mullerian hormone (AMH), and after excluding pregnancy 
and genetic, endocrinal, and other causes, she was diagnosed 
with POF.
Problems of quadrivalent HPV vaccine introduction in the 
market were wisely pointed by Little and Ward (25). They reported 
three other cases of young women who develop POF after having 
quadrivalent HPV vaccine and questioned some issues about its 
safety. First, despite the fact that the vaccine protocol suggests 
three doses, in the preclinical studies for toxicity, only two boost-
ers were given to the rats. Still, the animals’ reproductive system 
was not analyzed in a long-term period. Moreover, the phase 
II and III clinical studies on safety of the vaccine regarding the 
fertility were not complete: half of the subjects studied were lost 
to follow-up at 1 year; some of the subjects were on hormone con-
traception methods, which could mask the ovarian insufficiency; 
they have not considered medical conditions that flourished 
more than 7 months after the vaccination as associated with the 
vaccine; and adverse effects were only reported 2 weeks after the 
boosters. Furthermore, the placebo used as control in the phase 
III safety studies of the quadrivalent HPV vaccine was aluminum, 
also present in the vaccine solution, which was already shown to 
play as an adjuvant in ASIA syndrome.
Thus, HPV vaccine is likely to be an important trigger in ASIA 
syndrome, including immuno-mediated endocrine disorders, 
such as POF. Due to long periods of intervals between the vac-
cine injections and the development of the ovarian insufficiency, 
it is questionable if there is indeed a causal relationship between 
them. However, as previously mentioned, the safety preclinical 
and clinical studies of HPV vaccine are lacking some information 
regarding fertility safety, and the side effects were shown to be 
able to appear even after months or years.
Other vaccines and adjuvants may also trigger POF, as well 
as other immuno-mediated endocrinopathies, like for instance, 
type 1-diabetes may be induced by the same adjuvants. Indeed, in 
a cohort study with 211 young female patients with autoimmune 
diseases and 857 matched controls, they showed that patients 
exposed to quadrivalent HPV vaccine were in a higher risk of 
developing type 1-diabetes mellitus (OR = 1.2) (45). Additionally, 
it was shown in a prospective cohort study (46) that some vaccines 
are related to increased levels of diabetes autoantibodies, such 
as antibody against glutamic acid decarboxylase (GADA) and 
tyrosine phosphatase (IA-2A). These autoantibodies, which are 
considered reliable markers for the disease process (47, 48), were 
more frequently found in the subjects who received hemophilus 
influenza B (HIB) vaccination (OR = 5.9 and 3.4 in IA-2A and 
GADA, respectively). Especially, the IA-2A serum concentrations 
were significantly higher in patients exposed to HIB. Also, BCG 
was correlated to an enhanced prevalence of IA-2A (p < 0.01). 
The previously mentioned studies suggest that ASIA syndrome, 
particularly post vaccination, and endocrinopathies might be 
linked.
AUTOiMMUNe THYROiD DiSeASe  
AND ASiA SYNDROMe
During the last years, abundant case reports and series were 
published supporting that various autoimmune disorders may 
be induced by adjuvants and be enclosed under ASIA syndrome 
(4, 12). Despite the fact of being the most common autoimmune 
disorder, unexpectedly, we have revealed very few articles and 
case reports in the literature describing the induction of AITD 
by various adjuvants. In this section, we report that the relevant 
case descriptions of AITD were reported to be correlated to 
immunization and silicone implants.
Hernàn Martinez et al. (49) described a case of a 55-year-old 
man with a family history of autoimmune diseases and medical 
history of diabetes and psoriasis, who developed subacute thy-
roiditis shortly after the administration of an influenza vaccine. 
Subacute thyroiditis is a very rare disease, and the authors of the 
mentioned case concluded that the induction of the disease was 
a result of an interaction between the genetic predisposition and 
vaccination. Another similar case of subacute thyroiditis was 
reported in a 25-year-old female (50). The patient was admit-
ted due to fever, swelling, and tender mass in the neck. Two 
days before her presentation, she received influenza vaccine 
(Vaxigrip). Biopsy of the thyroid has revealed multinuclear giant 
cell granulomas.
A previously healthy 36-year-old female presented with clinical 
symptoms of thyrotoxicosis including tachycardia, anxiety, and 
tenderness in her neck (51). One month before her presentation, 
she received H1N1 vaccine. Thyroid function tests confirmed 
remarkable thyrotoxicosis. Thyroid scintigraphy was performed 
and showed significant diffuse reduction in the technetium 
uptake. Therefore, a diagnosis of subacute thyroiditis was made. 
Moving to another type of adjuvant, cases of granulomatous 
inflammation of the thyroid have been reported with silicone 
breast implants (52). Vayssairat et al. (53) described two cases of 
HT after receiving a silicone gel-filled breast implants. Both cases 
were induced after a long period of incubation, the first case is 
a 45-year-old women who had bilateral silicone implant of the 
breast in 1976 and developed HT in 1991. In addition, the patient 
complained of other non-specific symptoms including fatigue, 
morning stiffness, and sicca syndrome. Thyroid ultrasonography 
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showed an enlarged thyroid gland with a diffusely hypoecho-
genic pattern. The implants were painful and removed, showing 
extremely dense connective tissue with fibrosis. The second case 
of HT presented with hyperthyroidism clinical manifestation, 
10  years after the silicon implantation, reporting positive anti-
TPO. The implants were again painful, and the patient developed 
positive antinuclear antibodies (ANA). An animal experiment 
aimed to evaluate the immunological adjuvancy potential of 
silicone gel taken from breast implants (54). The study has found 
that silicone gel is able to stimulate the production of autoan-
tibodies to rat thyroglobulin and bovine collagen II. However, 
this immune reaction was not associated with any histological 
evidence of thyroiditis or arthritis.
A cohort study was performed to assess the risk of new onset 
autoimmune disease in young women exposed to human papillo-
mavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom 
(55). The study reported an incidence rate ratio (95% CI) of 3.75 
(1.25–11.31) for autoimmune thyroiditis among females.
An animal study has reported that immunization of BALB/c 
mice with the extracellular domain of the human TSH receptor 
led to the production of TSH binding-inhibiting and thyroid-
blocking antibodies accompanied by lymphocytic infiltration of 
the thyroid (56).
In summary, ASIA syndrome is being more recognized by 
physicians, and therefore, more studies and cases have reported 
the correlation of the exposure to various adjuvants with diverse 
autoimmune diseases. Still, very few clinical reports and animal 
models studies were published to show the relationship between 
endocrinopathies in general and AITD in particular with 
adjuvants. However, the clinical cases of HT and/or subacute 
thyroiditis were observed after the exposure to vaccines as well 
as silicone implantation. Therefore, we believe that the minority 
of cases is not owing to rarity of association between adjuvants 
and AITD rather than the lack of awareness among physicians of 
such association. Consequently, physicians must be mindful that 
thyroiditis and other thyroid disorders can be induced by diverse 
adjuvants and therefore to reconsider non-essential vaccination 
in genetically predisposed individuals for autoimmune diseases.
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